Edwards Lifesciences
In David Rolfe's portfolio · Wedgewood Partners
Ticker EW
Still in the portfolio as of Q2 2026. Every quarter it shows up in a Wedgewood Partners 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q2 2026 | Reduce 3% | 165,208 | 3.1% |
| Q1 2026 | Reduce 5% | 170,969 | 2.8% |
| Q4 2025 | Reduce 2% | 180,882 | 2.9% |
| Q3 2025 | Add 4% | 184,701 | 2.6% |
| Q2 2025 | Reduce 7% | 178,034 | 2.8% |
| Q1 2025 | Reduce 43% | 191,818 | 3.0% |
| Q4 2024 | Reduce 6% | 339,436 | 4.9% |
| Q3 2024 | Add 1% | 359,257 | 4.3% |
| Q2 2024 | Add 44% | 354,427 | 4.7% |
| Q1 2024 | Reduce 2% | 245,451 | 4.4% |
| Q4 2023 | Add 29% | 250,652 | 4.5% |
| Q3 2023 | Reduce 39% | 193,797 | 3.2% |
| Q2 2023 | Reduce 5% | 315,173 | 4.8% |
| Q1 2023 | Reduce 1% | 330,070 | 4.6% |
| Q4 2022 | Add 1% | 333,760 | 4.6% |
| Q3 2022 | Reduce 3% | 331,627 | 5.2% |
| Q2 2022 | Reduce 5% | 340,689 | 5.6% |
| Q1 2022 | Add 1% | 358,220 | 5.9% |
| Q4 2021 | Reduce 25% | 353,149 | 6.1% |
| Q3 2021 | Reduce 2% | 472,627 | 7.5% |
| Q2 2021 | Reduce 6% | 483,536 | 7.3% |
| Q1 2021 | Reduce 14% | 513,888 | 6.6% |
| Q4 2020 | Reduce 6% | 594,956 | 8.1% |
| Q3 2020 | Reduce 6% | 631,718 | 8.0% |
| Q2 2020 | Reduce 6%after split | 668,542 | 7.8% |
| Q1 2020 | Reduce 37% | 237,200 | 8.5% |
| Q4 2019 | Reduce 22% | 374,062 | 8.8% |
| Q3 2019 | Reduce 8% | 478,789 | 9.3% |
| Q2 2019 | Reduce 21% | 520,293 | 8.1% |
| Q1 2019 | Reduce 20% | 660,819 | 9.2% |
| Q4 2018 | No change | 821,132 | 8.3% |
| Q3 2018 | Reduce 8% | 818,960 | 7.1% |
| Q2 2018 | Reduce 21% | 891,410 | 6.6% |
| Q1 2018 | Reduce 15% | 1,132,341 | 7.3% |
| Q4 2017 | No change | 1,339,762 | 6.1% |
| Q3 2017 | Add 56% | 1,343,047 | 5.0% |
| Q2 2017 | Reduce 24% | 861,348 | 3.1% |
| Q1 2017 | Buy | 1,137,072 | 2.8% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.